Skip to main content


Treatment for Premature Ejaculation

ALZA Corporation Receives Letter From FDA on Dapoxetine Application

MOUNTAIN VIEW, Calif., October 26, 2005 -- ALZA Corporation announced today that it has received a not approvable letter from the U.S. Food and Drug Administration (FDA) on their New Drug Application for dapoxetine hydrochloride, an investigational compound for the treatment of premature ejaculation (PE).

ALZA Corporation is committed to developing safe and effective medicines that address important unmet medical needs. The company continues to believe that dapoxetine provides important benefits for men who suffer from PE. ALZA plans to address questions raised in the FDA letter and continue the global development program.

PE is a distinct medical condition that has been recognized by the American Urological Association (AUA), the American Psychiatric Association (APA) and the World Health Organization (WHO). PE can have a significant impact on many aspects of a man's life, including his and his partner's sexual satisfaction, the ability to build and maintain relationships, and a general sense of confidence. Currently, there are no drugs approved by the FDA for the treatment of PE. Traditional methods of PE treatment rely heavily on behavioral therapy and/or off-label use of older drugs that are approved for other conditions, all of which yield limited success.

Related Articles

Priligy (dapoxetine) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.